Mumbai: With a focus on shifting to Covid-19 treatment through oral pills, domestic companies, including Cipla, Dr.
Reddy’s, Sun Pharma and BDR Pharma, eyeing antivirus – including new drugs Pfizer, Paxlovid.
Most of these antiviruses are expected to be produced in this country and will be available at a fraction of the global price.
With Coronavirus to the endemic stage in several countries, mouth pills are expected to get a big market.
Recently, Pfizer announced positive results Paxlovid, which significantly reduced hospitalization and death.
It plans to submit data to authorize emergency use in the US soon.
“Pfizer wants to provide safe and effective oral antivirus therapy as soon as possible at an affordable price, subject to regulatory authorization,” said a company official.
On Tuesday, the US-based company was tied with Pool Pool (MPP) drugs that were not imposed to license drugs in 95 countries, including India.
MPP has invited an expression of interest from generic companies globally and will soon be a sub-license for making and sales.
Cipla said the Pfizer antivirus appealed to the company while Dr.
Reddy remained open to all opportunities.
A spokesman for Sun Pharma said: “It is our sustainable efforts to accelerate access to new drugs for Covid treatment in India and other markets.” These companies are between those who have been tied with Merck for the pill, which is expected to be launched at economical prices.
Industry experts expect it to be around? 1,200? 1,500 for the egoday course.
As the focus shifts to covid pills, Indian cos eye antivirus drugs affordable
